-
Oncology 1980The authors give a summarizing report about mitolactol treatments performed in Hungary. As a single-agent therapy the drug was administered in two forms: (1) every-day...
The authors give a summarizing report about mitolactol treatments performed in Hungary. As a single-agent therapy the drug was administered in two forms: (1) every-day therapy, 5 mg/kg/day, (2) push therapy, 10 mg/kg every 5th day or 15 mg/kg every 7th day, in a total dose of 100 mg/kg in both administration forms. Out of the solid tumours the squamous cell cancers proved to be the most responsive to mitolactol therapy: first of all in tumours of the head and neck and of the lung. The study also reports the preliminary results of polychemotherapeutical protocols containing mitolactol now in progress: (1) bleomycin + mitolactol (Bristol protocol), (2) carminomycin + mitolactol and (3) adriamycin + mitolactol.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Leukemia, Myeloid; Mitolactol
PubMed: 6935577
DOI: 10.1159/000225508 -
Cancer Treatment Reports Dec 1984Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of...
Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete regression; two patients had stable disease; and 35 patients had disease progression. The toxicity, which was primarily hematologic, was acceptable.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Mitolactol; Neoplasm Metastasis; Receptors, Estrogen
PubMed: 6548936
DOI: No ID Found -
Cancer Treatment Reports Oct 1984
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Mitolactol; Rectal Neoplasms
PubMed: 6525605
DOI: No ID Found -
Cancer Treatment Reports 1984Fifty-one patients (43 evaluable) with malignant melanoma were treated with mitolactol in an intermittent oral schedule. There were four objective tumor responses, all...
Fifty-one patients (43 evaluable) with malignant melanoma were treated with mitolactol in an intermittent oral schedule. There were four objective tumor responses, all occurring in patients previously treated with dacarbazine.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Mitolactol
PubMed: 6744338
DOI: No ID Found -
Cancer Treatment Reports 1981Thirty-two patients with metastatic breast cancer refractory to chemotherapy with combinations of cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone were... (Clinical Trial)
Clinical Trial
Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
Thirty-two patients with metastatic breast cancer refractory to chemotherapy with combinations of cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone were treated with doxorubicin, mitolactol (dibromodulcitol), and mitomycin C. Two complete and 12 partial remissions were observed for a response rate of 435. When only those patients who were considered evaluable were included (the 26 patients who had received more than one course of therapy), the response rate was 53%. Hematologic toxicity was moderate-to-severe. Responses were seen in visceral, osseous, and soft tissue tumor sites. The median time to the development of disease progression was 30 weeks for responding patients. The median survival of responders has not yet been reached at 48 weeks.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Mitolactol; Mitomycins; Neoplasm Metastasis; Prognosis
PubMed: 7013977
DOI: No ID Found -
Seminars in Surgical Oncology 1999Chemotherapy is used primarily to treat advanced or recurrent cervical cancer. There are three major applications: primary therapy, as a radiation sensitizer, and... (Review)
Review
Chemotherapy is used primarily to treat advanced or recurrent cervical cancer. There are three major applications: primary therapy, as a radiation sensitizer, and neoadjuvant therapy. Primary chemotherapy is employed in advanced and disseminated cervical carcinoma (Stage VB). The four best single drugs with moderate activity against cervical cancer are: cisplatin, ifosfamide, dibromodulcitol (mitolactol), and Adriamycin (doxorubicin). Cisplatin and ifosfamide appear to be the best combination therapy: they provide an objective response rate of 33%. However, because the overall survival was not significantly improved with combination therapy, single-agent therapy with one of the above active drugs is acceptable. For stages IIB, III and IVA, the primary therapy is still radiation. Concomitant chemotherapy with hydroxyurea or a combination of cisplatin and 5-fluorouracil (5-FU) have been shown to enhance radiation response in several randomized trials. Hydroxyurea is the preferred radiation sensitizer because it offers less toxicity, ease of administration, and equivalent results. Chemotherapy in neoadjuvant setting produces promising results. Various cisplatin combinations of mitomycin C, 5-FU, vincristine, and bleomycin have been employed to shrink locally advanced cervical cancer and permit safe, radical excision. Early results with these combinations in small trials are encouraging but further studies are needed to fully evaluate their potential.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Uterine Cervical Neoplasms
PubMed: 10225304
DOI: 10.1002/(sici)1098-2388(199904/05)16:3<247::aid-ssu10>3.0.co;2-4 -
Cancer Treatment Reports 1985One hundred thirty patients with previously treated advanced breast cancer were treated in a cooperative trial to investigate the effect of mitomycin plus tamoxifen (MT)... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
One hundred thirty patients with previously treated advanced breast cancer were treated in a cooperative trial to investigate the effect of mitomycin plus tamoxifen (MT) and to compare its relative value to combination therapy with mitolactol, doxorubicin (ADM), and tamoxifen. An additional 76 patients who had had prior exposure to ADM were randomized to receive MT or MT plus fluoxymesterone. MT versus mitolactol, ADM, and tamoxifen was not significantly different in efficacy; however, there were significant differences in toxicity. This study showed that MT is an effective and acceptable second-line treatment for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Female; Fluoxymesterone; Humans; Leukocyte Count; Middle Aged; Mitolactol; Mitomycin; Mitomycins; Platelet Count; Random Allocation; Tamoxifen; Thioguanine
PubMed: 4016786
DOI: No ID Found -
Journal of Clinical Oncology : Official... Apr 1994
Topics: Acute Disease; Adult; Aged; Breast Neoplasms; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitolactol; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors
PubMed: 8151329
DOI: 10.1200/JCO.1994.12.4.874 -
Journal of Clinical Oncology : Official... Dec 1989Sixty patients with advanced squamous cell carcinoma of the cervix (SCC) who had received no prior chemotherapy were entered onto a study of mitolactol (dibromodulcitol... (Clinical Trial)
Clinical Trial
Sixty patients with advanced squamous cell carcinoma of the cervix (SCC) who had received no prior chemotherapy were entered onto a study of mitolactol (dibromodulcitol [DBD]). The drug was administered orally at an initial dose of 180 mg/m2 per day for 10 days and repeated every 4 weeks. There were 55 evaluable patients, of whom one (2%) had a complete response (CR), and 15 (27%) had a partial response (PR), (CR plus PR, 29%). A 95% confidence interval for the true response rate is 18.8% to 42.1%. Myelosuppression was appreciable at this dose and schedule, with 13 patients experiencing life-threatening thrombocytopenia and two drug-related deaths. The level of activity in this disease encourages us to determine a tolerable dose of this drug in combination with cisplatin for further study.
Topics: Adult; Aged; Bone Marrow; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Middle Aged; Mitolactol; Multicenter Studies as Topic; Uterine Cervical Neoplasms
PubMed: 2685182
DOI: 10.1200/JCO.1989.7.12.1892 -
Cancer Treatment Reports Jan 1985The Central Pennsylvania Oncology Group conducted a phase II study of mitolactol in advanced metastatic melanoma to determine the overall survival rate and duration of...
The Central Pennsylvania Oncology Group conducted a phase II study of mitolactol in advanced metastatic melanoma to determine the overall survival rate and duration of response to this agent. The starting dose was 100 mg/m2/day orally. If no hematologic toxicity was noted on weekly blood cell counts, the dose was increased to 130 mg/m2/day on Day 35, and, if still tolerated, to 160 mg/m2/day on Day 70. Six of 25 evaluable patients (24%) had objective partial response. The median duration of response was 20 weeks, with a range of 10-66 weeks. Six of 25 patients (24%) had stable measurable disease, with a median duration of 9 weeks. The median survival from date of entry in this study was 21 weeks in responding or stable patients compared to 7 weeks in nonresponders. Hematologic toxicity was the dose-limiting factor. This study shows that mitolactol has moderate activity against advanced melanoma, and the drug deserves further study in combination with nonmyelotoxic drugs.
Topics: Adult; Aged; Bone Marrow; Drug Evaluation; Female; Hemoglobins; Humans; Leukocyte Count; Male; Melanoma; Middle Aged; Mitolactol; Neoplasm Metastasis; Platelet Count
PubMed: 3967260
DOI: No ID Found